Literature DB >> 15385112

A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?

Teresa L Rutledge1, Scott A Kamelle, Todd D Tillmanns, Natalie S Gould, Jason D Wright, David E Cohn, Thomas J Herzog, Janet S Rader, Michael A Gold, Gary A Johnson, Joan L Walker, Robert S Mannel, D Scott McMeekin.   

Abstract

OBJECTIVE: To compare stages IB1 and IB2 cervical cancers treated with radical hysterectomy (RH) and to define predictors of nodal status and recurrence.
METHODS: Patients with stage IB cervical cancers undergoing RH between 1990 and 2000 were evaluated and clinicopathological variables were abstracted. The perioperative complication rate, estimated blood loss (EBL), and OR time were also tabulated. Variables were analyzed using X(2) and t tests. Disease-free survival (DFS) was calculated by Kaplan-Meier method. Multivariate analysis was performed via stepwise logistic regression. Cox-proportional hazards were used to identify independent predictors of recurrence.
RESULTS: RH was performed on 109 stage IB1 and 86 stage IB2 patients. Mean age, EBL, and perioperative complication rates were similar. Overall, 38 patients (14 IB1 vs. 24 IB2) had positive nodes (P = 0.01) including 9 patients with positive para-aortic nodes (2 IB1 and 7 IB2). Parametrial involvement (PI) and outer 2/3 depth of invasion (DOI) were significantly more common in the IB2 tumors as well. Patients with IB2 disease received adjuvant radiation more frequently than IB1 patients (52% vs. 37%, P = 0.04). Univariate predictors of nodal status included lymphovascular space involvement (LVSI) (P = 0.001), DOI (P = 0.011), PI (P = 0.001), and stage (P = 0.011). Multivariate analysis identified only LVSI (OR 6.4, CI 2.4-17, P = 0. 0002) and PI (OR 8, CI 3.1-20, P = 0. 0001) as independent predictors of positive nodes. With a median follow-up of 35 months, estimates of DFS revealed tumor size (P = 0.008), nodal status (P = 0.0004), LVSI (P = 0.002), PI (P = 0.004), and DOI (P = 0.0004) as significant univariate predictors. Neoadjuvant chemotherapy, age, grade, histology, and adjuvant radiation were not associated with recurrence. The significant independent predictors of DFS were LVSI (ROR 5.7, CI 2-16, P = 0.0064) and outer 2/3 DOI (OR 5.8, CI 2-20, P = 0.0029). Neither tumor size nor nodal status was a significant predictor of DFS.
CONCLUSIONS: The prognosis in stage IB cervical cancer seems to be most influenced by presence of LVSI and DOI and not by tumor size as the staging criteria would suggest. These factors are best determined pathologically after radical hysterectomy. This report contains the largest comparison of IB1 and IB2 patients managed by RH. Tumor size failed to predict recurrence or nodal status when stratified by LVSI, DOI, and PI. Treatment decisions based on tumor size alone should be reconsidered.

Entities:  

Mesh:

Year:  2004        PMID: 15385112     DOI: 10.1016/j.ygyno.2004.07.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines.

Authors:  Jason D Wright; Koji Matsuo; Yongmei Huang; Ana I Tergas; June Y Hou; Fady Khoury-Collado; Caryn M St Clair; Cande V Ananth; Alfred I Neugut; Dawn L Hershman
Journal:  Obstet Gynecol       Date:  2019-07       Impact factor: 7.661

2.  Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.

Authors:  E R Nijhuis; H W Nijman; K A Oien; A Bell; K A ten Hoor; N Reesink-Peters; H M Boezen; H Hollema; A G J van der Zee
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

3.  Treatment and Outcomes of Early and Operable Recurrent Cervical Cancer: A Prospective Study.

Authors:  Nikhil Mehta; Sanjay M Desai; Vinod Dhakad; Dhruv Patel; Elroy Saldanha
Journal:  Niger J Surg       Date:  2021-03-09

4.  Cost-utility analysis of treatments for stage IB cervical cancer.

Authors:  Kanyarat Katanyoo; Naiyana Praditsitthikorn; Siriwan Tangjitgamol; Sumonmal Manusirivithaya; Busaba Supawattanabodee
Journal:  J Gynecol Oncol       Date:  2014-04-09       Impact factor: 4.401

5.  Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risks and lymph-vascular space involvement.

Authors:  Yue Wang; Guang Wang; Li-Hui Wei; Ling-Hui Huang; Jian-Liu Wang; Shi-Jun Wang; Xiao-Ping Li; Dan-Hua Shen; Dong-Mei Bao; Jian Gao
Journal:  Chin J Cancer       Date:  2011-09

Review 6.  Management of Early-Stage Cervical Cancer: A Literature Review.

Authors:  Yasmin Medeiros Guimarães; Luani Rezende Godoy; Adhemar Longatto-Filho; Ricardo Dos Reis
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

7.  Application of gene expression programming and neural networks to predict adverse events of radical hysterectomy in cervical cancer patients.

Authors:  Maciej Kusy; Bogdan Obrzut; Jacek Kluska
Journal:  Med Biol Eng Comput       Date:  2013-10-18       Impact factor: 2.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.